TABLE 2.
Evolution of immunovirological parameters and proportion of VRs through week 48
| Time of analysis | Median (IQR) HIV RNA load (log) | Median (IQR) HIV RNA load variation (log) from baseline | No. (%) of subjects with VRa | No. (%) of subjects with <50 HIV RNA copies/ml | Median (IQR) CD4+ cell count (cells/mm3) | Median (IQR) CD4+ variation (cells/mm3) from baseline |
|---|---|---|---|---|---|---|
| Baseline | 4.75 (4.19-5.14) | 0 (0) | 241 (100-399) | |||
| Wk 12 | 2.07 (<1.7-4.31) | −2.08 (−3.3, −0.5) | 23 (60.5) | 16 (42.1) | 262 (185-402) | +24 (−29, +125) |
| Wk 24 | 2.14 (<1.7-4.25) | 2.1 (−2.9, −0.7) | 25 (65.8) | 14 (36.8) | 297 (184-449) | +40 (−14, +161) |
| Wk 48 | 2.36 (<1.7-4.45) | −1.48 (−2.88, −0.48) | 20 (52.6) | 15 (39.5) | 323 (181-459) | +37 (−30, +175) |
a
VR was considered an HIV RNA load decrease of >1 and/or <50 copies/ml, with no HIV RNA increase >0.5 log compared to the maximal viral load decrease.